Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?
The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a late-stage clinical study.
Why Summit Therapeutics Skyrocketed 123% This Week
Shares of
Summit
Therapeutics
(NASDAQ: SMMT) rocketed 123.4% higher this week through Thursday trading, according to data from S&P Global Market Intelligence. A biotech stock surging that much ...
Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale
Summit Therapeutics stock rocketed again Thursday — adding onto an 85% gain this week — after raising $235 million in a private placement.
Why Summit Therapeutics Stock Is Soaring Again Today
Investors were undoubtedly especially glad to see key insiders agree to buy more Summit Therapeutics stock. Together, co-CEOs Robert W. Duggan and Mahkam Zanganeh, chief operating officer (COO)/CFO Manmeet Soni, chief accounting officer Bhaskar Anand, and board member Jeff Huber are purchasing over 3.48 million shares.
21h
Iranian Immigrant Becomes Billionaire As Her Biotech Firm’s Stock Soars
Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...
3d
Here's Why Everyone's Talking About Summit Therapeutics
Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...
Investor's Business Daily on MSN
3d
How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A Recovery
BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...
1d
Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...
BioSpace
2d
Despite Win Over Keytruda, Summit’s NSCLC Bispecific Still Has Something to Prove
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
11d
on MSN
Summit Therapeutics’ stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial
Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage ...
BioPharma Dive
1d
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...
STAT
11d
With a win in lung cancer, biotech’s wealthiest outsider surfs to new heights
Summit’s lung cancer treatment has wowed researchers. The CEO behind it is a living challenge to the assumptions of many in ...
11d
Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)
Summit Therapeutics' ivonescimab shows a significant PFS improvement over pembrolizumab in NSCLC. Read why I'm bearish on ...
Barchart on MSN
4d
Up 1,123% YTD, Is It Too Late to Buy This Breakout Biotech Stock?
The biotech space is incredibly exciting, given that companies are investing heavily to treat and prevent diseases. In fact, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
BioNTech
ivonescimab
NASDAQ
Merck & Co.
Pembrolizumab
Feedback